| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Departments of Surgery [K. S., J. J. M.] and Internal Medicine [J. J. M.], and the Tumor Immunology and Immunotherapy Program of the Comprehensive Cancer Center [J. J. M.], University of Michigan Medical Center, Ann Arbor, Michigan 48103-0666; Extramural Research, Immunex Corporation, Seattle, Washington 98101 [E. K. T.]; and Vaccines and Gene Therapy Research, Chiron Technologies, 4560 Horton Street, Emeryville, California 94608-2916 [M. G.]
We have evaluated whether the addition of a foreign helper protein, keyhole limpet hemocyanin (KLH), can augment the efficacy of tumor lysate-pulsed dendritic cells and peptide-pulsed DC immunizations in vivo. Besides being used as a "surrogate antigen" in approaches to measure immunological response in cancer patients, KLH is also an immunogenic carrier protein to elicit T-cell help. Using the D5 subline of B16 melanoma, we demonstrate that DCs pulsed with both KLH and tumor lysate mediate enhanced immune priming and rejection of established metastases in vivo, which is dependent on host-derived T cells. Interleukin 2 augments the enhancement afforded by KLH, as measured by cure rates and overall survival, in the absence of autoimmune depigmentation. KLH added to DC immunizations markedly enhances tumor-specific T cell production of IFN-
. D5 melanoma exposed to similar levels of IFN-
results in substantial expression of MHC class I molecules. DCs pulsed with KLH and mouse tyrosinase-related protein-2 peptide results in enhanced reduction of B16 melanoma metastases; the effect is most pronounced in a setting where tyrosinase-related protein-2 peptide-pulsed DCs alone are completely ineffective. Collectively, these findings demonstrate that KLH addition to tumor antigen-pulsed DC immunizations can augment IFN-
production and enhance in vivo antitumor activity.
This article has been cited by other articles:
![]() |
S.-i. Fujii, A. Goto, and K. Shimizu Antigen mRNA-transfected, allogeneic fibroblasts loaded with NKT-cell ligand confer antitumor immunity Blood, April 30, 2009; 113(18): 4262 - 4272. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-G. de Goer de Herve, A. Cariou, F. Simonetta, and Y. Taoufik Heterospecific CD4 Help to Rescue CD8 T Cell Killers J. Immunol., November 1, 2008; 181(9): 5974 - 5980. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grolleau-Julius, E. K. Harning, L. M. Abernathy, and R. L. Yung Impaired Dendritic Cell Function in Aging Leads to Defective Antitumor Immunity Cancer Res., August 1, 2008; 68(15): 6341 - 6349. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Kochenderfer and R. E. Gress A Comparison and Critical Analysis of Preclinical Anticancer Vaccination Strategies Experimental Biology and Medicine, October 1, 2007; 232(9): 1130 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, F. Tanaka, H. Nagahara, K. Ieta, N. Haraguchi, K. Mimori, A. Sasaki, H. Inoue, K. Yanaga, and M. Mori Opa Interacting Protein 5 (OIP5) Is a Novel Cancer-testis Specific Gene in Gastric Cancer Ann. Surg. Oncol., February 1, 2007; 14(2): 885 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Ji, D. Gondek, and A. A. Hurwitz Provision of Granulocyte-Macrophage Colony-Stimulating Factor Converts an Autoimmune Response to a Self-Antigen into an Antitumor Response J. Immunol., August 1, 2005; 175(3): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wu, T. Wan, X. Zhou, B. Wang, F. Yang, N. Li, G. Chen, S. Dai, S. Liu, M. Zhang, et al. Hsp70-Like Protein 1 Fusion Protein Enhances Induction of Carcinoembryonic Antigen-Specific CD8+ CTL Response by Dendritic Cell Vaccine Cancer Res., June 1, 2005; 65(11): 4947 - 4954. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Goldszmid, J. Idoyaga, A. I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma J. Immunol., December 1, 2003; 171(11): 5940 - 5947. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Teramoto, K. Kontani, Y. Ozaki, S. Sawai, N. Tezuka, T. Nagata, S. Fujino, Y. Itoh, O. Taguchi, Y. Koide, et al. Deoxyribonucleic Acid (DNA) Encoding a Pan-Major Histocompatibility Complex Class II Peptide Analogue Augmented Antigen-specific Cellular Immunity and Suppressive Effects on Tumor Growth Elicited by DNA Vaccine Immunotherapy Cancer Res., November 15, 2003; 63(22): 7920 - 7925. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sato, K. Chamoto, and T. Nishimura A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells Int. Immunol., July 1, 2003; 15(7): 837 - 843. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Pilon, C. Kelly, and W.-Z. Wei Broadening of Epitope Recognition During Immune Rejection of ErbB-2-Positive Tumor Prevents Growth of ErbB-2-Negative Tumor J. Immunol., February 1, 2003; 170(3): 1202 - 1208. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Holtl, C. Zelle-Rieser, H. Gander, C. Papesh, R. Ramoner, G. Bartsch, H. Rogatsch, A. L. Barsoum, J. H. Coggin Jr., and M. Thurnher Immunotherapy of Metastatic Renal Cell Carcinoma with Tumor Lysate-pulsed Autologous Dendritic Cells Clin. Cancer Res., November 1, 2002; 8(11): 3369 - 3376. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Knutson, K. Schiffman, M. A. Cheever, and M. L. Disis Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369-377, Results in Short-lived Peptide-specific Immunity Clin. Cancer Res., May 1, 2002; 8(5): 1014 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Chang, B. G. Redman, J. R. Whitfield, B. J. Nickoloff, T. M. Braun, P. P. Lee, J. D. Geiger, and J. J. Mule A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer Clin. Cancer Res., April 1, 2002; 8(4): 1021 - 1032. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Geiger, R. J. Hutchinson, L. F. Hohenkirk, E. A. McKenna, G. A. Yanik, J. E. Levine, A. E. Chang, T. M. Braun, and J. J. Mule Vaccination Of Pediatric Solid Tumor Patients with Tumor Lysate-pulsed Dendritic Cells Can Expand Specific T Cells and Mediate Tumor Regression Cancer Res., December 1, 2001; 61(23): 8513 - 8519. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |